{"disease":{"id":"idiopathic-pulmonary-fibrosis","name":"Idiopathic Pulmonary Fibrosis (IPF)","therapeutic_area":"Respiratory","data":{"aiSummary":"The treatment landscape for IPF is evolving, with the current standard of care focused on slowing disease progression using antifibrotic agents like nintedanib. Several therapies are in development, targeting various mechanisms, including autotaxin and integrin inhibition. While marketed drugs provide benefit, the search for more effective and tolerable treatments continues, with a focus on personalized approaches and combination therapies. The pipeline includes both small molecules and biologics, aiming to address the unmet needs of patients with progressive disease.","drug_count":4,"description":"Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring (fibrosis) of the lungs. The cause is unknown, leading to progressive decline in lung function and ultimately respiratory failure. Current treatments aim to slow disease progression, but a cure remains elusive.","subtype_count":8},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.937Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nintedanib","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ofev","generic_name":"NINTEDANIB","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"Kinase Inhibitor","quality_score":70,"revenue":"2000","mechanism":"Ofev works by blocking enzymes that promote fibrosis and tumor growth."},{"drug_id":"ofev","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OFEV®","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"Kinase Inhibitor","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"nerandomilast","indication_name":"Idiopathic Pulmonary Fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jascayd","generic_name":"NERANDOMILAST","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Jascayd works by inhibiting the activity of phosphodiesterase 4, an enzyme involved in the inflammatory response."},{"drug_id":"vargatef","indication_name":"Idiopathic pulmonary fibrosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"vargatef","company_name":"ARCAGY/ GINECO GROUP","drug_phase":"discontinued","molecular_target":"Calcium/calmodulin-dependent protein kinase type IV, Cyclin-dependent kinase 18, Cyclin-dependent kinase-like 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03958071","title":"A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking","phase":"","overall_status":"COMPLETED","enrollment_count":13264,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06485635","title":"Real-life-persistence to Antifibrotic Treatments","phase":"","overall_status":"COMPLETED","enrollment_count":10646,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT02607722","title":"All-Case Surveillance of Ofev in Patients With IPF in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":10117,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05382572","title":"Pulmonary Fibrosis Foundation Community Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT07178392","title":"Disease-syndrome Characteristics of IPF","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2864,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05779007","title":"Dose Reduction and Discontinuation With Anti-Fibrotic Medications","phase":"","overall_status":"COMPLETED","enrollment_count":2778,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04896138","title":"University of Virginia Natural History Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2500,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT02758808","title":"Pulmonary Fibrosis Foundation Patient Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2004,"lead_sponsor_name":"Pulmonary Fibrosis Foundation","has_results":false},{"nct_id":"NCT05022784","title":"Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1798,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05870956","title":"Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1798,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06238622","title":"A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1700,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03120481","title":"Controls for Respiratory Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1572,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06003426","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1255,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05321069","title":"A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1177,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02699879","title":"Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)","phase":"","overall_status":"COMPLETED","enrollment_count":1009,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07162870","title":"Idiopathic Pulmonary Fibrosis Cohort of TCM","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT03478553","title":"The Genetics of Pulmonary Fibrosis","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT07404423","title":"OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Modena and Reggio Emilia","has_results":false},{"nct_id":"NCT05842681","title":"Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05392881","title":"Interstitial Lung Disease Research Unit Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT03211507","title":"Idiopathic Pulmonary Fibrosis Job Exposures Study","phase":"","overall_status":"COMPLETED","enrollment_count":960,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04016168","title":"Idiopathic Pulmonary Fibrosis and Serum Bank","phase":"","overall_status":"COMPLETED","enrollment_count":903,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT03666234","title":"Idiopathic Pulmonary Fibrosis Registry China Study","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Dai Huaping","has_results":false},{"nct_id":"NCT07520110","title":"Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT04016181","title":"The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03733444","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":781,"lead_sponsor_name":"Galapagos NV","has_results":true},{"nct_id":"NCT01619085","title":"Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT03437486","title":"Mechanisms of Familial Pulmonary Fibrosis","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT05028894","title":"23andMe IPF Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":690,"lead_sponsor_name":"23andMe, Inc.","has_results":false},{"nct_id":"NCT04552899","title":"A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":665,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06521125","title":"Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04708782","title":"Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"United Therapeutics","has_results":false},{"nct_id":"NCT05255991","title":"Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":597,"lead_sponsor_name":"United Therapeutics","has_results":false},{"nct_id":"NCT04263727","title":"A Study of Patients With Chronic Disease","phase":"","overall_status":"TERMINATED","enrollment_count":579,"lead_sponsor_name":"Target PharmaSolutions, Inc.","has_results":false},{"nct_id":"NCT03732859","title":"PROOF-Registry New and Extended Belgium -Luxembourg","phase":"","overall_status":"COMPLETED","enrollment_count":575,"lead_sponsor_name":"Belgian Thoracic Society","has_results":false},{"nct_id":"NCT01769196","title":"Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":544,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03711162","title":"A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":525,"lead_sponsor_name":"Galapagos NV","has_results":true},{"nct_id":"NCT02759120","title":"CleanUP IPF for the Pulmonary Trials Cooperative","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":513,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07464912","title":"A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT01872689","title":"A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03747627","title":"BPF Genetics of ILD Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"University of Dundee","has_results":false},{"nct_id":"NCT07082842","title":"Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":472,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT03457935","title":"Detection of Early Idiopathic Pulmonary Fibrosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"Temple University","has_results":false},{"nct_id":"NCT00287716","title":"Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03955146","title":"Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":393,"lead_sponsor_name":"Kyntra Bio","has_results":true},{"nct_id":"NCT06914713","title":"Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":384,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT04419558","title":"Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":372,"lead_sponsor_name":"Kyntra Bio","has_results":true},{"nct_id":"NCT02788474","title":"Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":347,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06951217","title":"An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Avalyn Pharma Inc.","has_results":false},{"nct_id":"NCT02345070","title":"Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":327,"lead_sponsor_name":"Sanofi","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}